AU2016312848A1 - Inhibitors of tryptophan dioxygenases (IDO1 and TDO) and their use in therapy - Google Patents

Inhibitors of tryptophan dioxygenases (IDO1 and TDO) and their use in therapy Download PDF

Info

Publication number
AU2016312848A1
AU2016312848A1 AU2016312848A AU2016312848A AU2016312848A1 AU 2016312848 A1 AU2016312848 A1 AU 2016312848A1 AU 2016312848 A AU2016312848 A AU 2016312848A AU 2016312848 A AU2016312848 A AU 2016312848A AU 2016312848 A1 AU2016312848 A1 AU 2016312848A1
Authority
AU
Australia
Prior art keywords
optionally substituted
alkyl
group
independently selected
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2016312848A
Other languages
English (en)
Inventor
Lai-Ming Ching
Brian Desmond Palmer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Auckland Uniservices Ltd
Original Assignee
Auckland Uniservices Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auckland Uniservices Ltd filed Critical Auckland Uniservices Ltd
Publication of AU2016312848A1 publication Critical patent/AU2016312848A1/en
Priority to AU2021212003A priority Critical patent/AU2021212003B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AU2016312848A 2015-08-27 2016-08-25 Inhibitors of tryptophan dioxygenases (IDO1 and TDO) and their use in therapy Abandoned AU2016312848A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2021212003A AU2021212003B2 (en) 2015-08-27 2021-08-03 INHIBITORS OF TRYPTOPHAN DIOXYGENASES (IDO1 and TDO) AND THEIR USE IN THERAPY

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NZ71151415 2015-08-27
NZ711514 2015-08-27
PCT/NZ2016/050135 WO2017034420A1 (en) 2015-08-27 2016-08-25 Inhibitors of tryptophan dioxygenases (ido1 and tdo) and their use in therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021212003A Division AU2021212003B2 (en) 2015-08-27 2021-08-03 INHIBITORS OF TRYPTOPHAN DIOXYGENASES (IDO1 and TDO) AND THEIR USE IN THERAPY

Publications (1)

Publication Number Publication Date
AU2016312848A1 true AU2016312848A1 (en) 2018-03-29

Family

ID=58100623

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2016312848A Abandoned AU2016312848A1 (en) 2015-08-27 2016-08-25 Inhibitors of tryptophan dioxygenases (IDO1 and TDO) and their use in therapy
AU2021212003A Active AU2021212003B2 (en) 2015-08-27 2021-08-03 INHIBITORS OF TRYPTOPHAN DIOXYGENASES (IDO1 and TDO) AND THEIR USE IN THERAPY

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2021212003A Active AU2021212003B2 (en) 2015-08-27 2021-08-03 INHIBITORS OF TRYPTOPHAN DIOXYGENASES (IDO1 and TDO) AND THEIR USE IN THERAPY

Country Status (9)

Country Link
US (2) US11414428B2 (cg-RX-API-DMAC10.html)
EP (1) EP3350188B1 (cg-RX-API-DMAC10.html)
JP (2) JP7334041B2 (cg-RX-API-DMAC10.html)
KR (1) KR20180048798A (cg-RX-API-DMAC10.html)
CN (1) CN108349997B (cg-RX-API-DMAC10.html)
AU (2) AU2016312848A1 (cg-RX-API-DMAC10.html)
CA (1) CA2996681C (cg-RX-API-DMAC10.html)
WO (1) WO2017034420A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201800787B (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2996681C (en) * 2015-08-27 2024-04-09 Auckland Uniservices Limited Inhibitors of tryptophan dioxygenases (ido1 and tdo) and their use in therapy
US11103511B2 (en) 2017-06-05 2021-08-31 Fudan University Substituted indolo[2,1-b]quinazolines as inhibitors of tryptophan dioxygenase and indoleamine 2,3-dioxygenase 1
GB201809050D0 (en) 2018-06-01 2018-07-18 E Therapeutics Plc Modulators of tryptophan catabolism
TWI873098B (zh) 2018-07-03 2025-02-21 瑞士商諾華製藥公司 用於治療與sting活性相關之病症的化合物及組合物
JP2024502474A (ja) 2021-01-08 2024-01-19 アイエフエム デュー インコーポレイテッド Sting活性に関連する状態を治療するための、尿素を有するヘテロ二環式化合物または類似体およびその組成物
BR112023017582A2 (pt) 2021-03-05 2023-12-05 Univ Basel Composições para o tratamento de doenças ou condições associadas ao ebv
EP4052705A1 (en) 2021-03-05 2022-09-07 Universität Basel Vizerektorat Forschung Compositions for the treatment of ebv associated diseases or conditions
EP4486342A2 (en) 2022-03-04 2025-01-08 Antido Therapeutics International Sàrl Dual inhibitors of tryptophan dioxygenases (ido1 and tdo) and their use in therapy

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001079193A2 (en) 2000-04-14 2001-10-25 Corvas International, Inc. Substituted hydrazinyl heteroaromatic inhibitors of thrombin
WO2005089753A2 (en) * 2004-03-16 2005-09-29 Janssen Pharmaceutica N.V. Daao inhibiting bξnzisoxazoles and their use for the treatment of mental disorders
TW200633990A (en) * 2004-11-18 2006-10-01 Takeda Pharmaceuticals Co Amide compound
DE102005018389A1 (de) * 2005-04-20 2006-10-26 Sanofi-Aventis Deutschland Gmbh Azolderivate als Inhibitoren von Lipasen und Phospholipasen
DE102005038947A1 (de) * 2005-05-18 2006-11-30 Grünenthal GmbH Substituierte Benzo[d]isoxazol-3-yl-amin-Verbindungen und deren Verwendung in Arzneimitteln
DE102005026194A1 (de) * 2005-06-06 2006-12-07 Grünenthal GmbH Substituierte N-Benzo[d]isoxazol-3-yl-amin-Derivate und deren Verwendung zur Herstellung von Arzneimitteln
WO2009073620A2 (en) 2007-11-30 2009-06-11 Newlink Genetics Ido inhibitors
US8461159B2 (en) 2008-11-25 2013-06-11 Jannsen Pharmaceutica BV Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
US8598356B2 (en) * 2008-11-25 2013-12-03 Janssen Pharmaceutica Nv Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
JP2012520246A (ja) 2009-03-10 2012-09-06 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Kcnq2/3モジュレータとしての置換された3−アミノイソオキサゾロピリジン
MX2012009377A (es) 2010-02-11 2012-09-12 Univ Vanderbilt Benzotiazoles y azabenzotiazoles como potenciadores alostericos mglur4, composiciones y metodos para tratar la disfuncion neurologica.
BR112013001474B8 (pt) 2010-07-22 2018-05-22 Basf Se uso de compostos de isoxazolo[5,4-b]piridina, compostos de isoxazolo[5,4-b]piridina, composição, método para preparar uma composição e método para controlar vegetação indesejada
BR112014017209A8 (pt) 2012-01-12 2017-07-04 Basf Se compostos, composição, método para a preparação de uma composição e método para o controle da vegetação indesejável
PL220630B1 (pl) 2012-12-28 2015-11-30 Inst Immunologii I Terapii Doświadczalnej Pan Nowe sulfonamidowe pochodne izoksazolo[5,4-b]pirydyny o aktywności przeciwbakteryjnej, sposób ich wytwarzania oraz nowe zastosowanie 3-aminoizoksazolo[5,4-b]pirydyny
JP6603649B2 (ja) 2013-03-14 2019-11-06 キュラデブ ファーマ プライベート リミテッド キヌレニン経路の阻害剤
EP3082802B1 (en) 2013-12-03 2020-02-26 Iomet Pharma Ltd. Tryptophan-2,3-dioxygenase (tdo) and/or indolamine-2,3-dioxygenase (ido) inhibitors and their use
WO2016024233A1 (en) * 2014-08-13 2016-02-18 Auckland Uniservices Limited Inhibitors of tryptophan dioxygenases (ido1 and tdo) and their use in therapy
CA2996681C (en) * 2015-08-27 2024-04-09 Auckland Uniservices Limited Inhibitors of tryptophan dioxygenases (ido1 and tdo) and their use in therapy
RU2619120C1 (ru) * 2016-06-06 2017-05-12 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Кубанский государственный аграрный университет" 5-Хлор-3-(3-хлорфенилкарбоксамидо)-4,6-диметилизоксазоло[5,4-b]пиридин в качестве антидота 2,4-Д на подсолнечнике

Also Published As

Publication number Publication date
CN108349997A (zh) 2018-07-31
AU2021212003A1 (en) 2021-08-26
JP2018525430A (ja) 2018-09-06
WO2017034420A1 (en) 2017-03-02
JP7334041B2 (ja) 2023-08-28
KR20180048798A (ko) 2018-05-10
US20220411438A1 (en) 2022-12-29
CA2996681A1 (en) 2017-03-02
ZA201800787B (en) 2025-08-27
CN108349997B (zh) 2025-06-10
US20180244692A1 (en) 2018-08-30
EP3350188A1 (en) 2018-07-25
HK1258665A1 (en) 2019-11-15
AU2021212003B2 (en) 2023-09-14
EP3350188A4 (en) 2019-04-03
JP2022033753A (ja) 2022-03-02
US11414428B2 (en) 2022-08-16
CA2996681C (en) 2024-04-09
EP3350188B1 (en) 2024-03-13

Similar Documents

Publication Publication Date Title
AU2021212003B2 (en) INHIBITORS OF TRYPTOPHAN DIOXYGENASES (IDO1 and TDO) AND THEIR USE IN THERAPY
US12508268B2 (en) Inhibitors of tryptophan dioxygenases (IDO1 and TDO) and their use in therapy
EP4004002B1 (en) Macrocyclic compounds as sting agonists and methods and uses thereof
JP6830948B2 (ja) Midh1阻害剤としての縮合イミダゾール
HK1258665B (en) Inhibitors of tryptophan dioxygenases (ido1 and tdo) and their use in therapy
HK1238549A1 (en) Inhibitors of tryptophan dioxygenases (ido1 and tdo) and their use in therapy
HK1238549B (en) Inhibitors of tryptophan dioxygenases (ido1 and tdo) and their use in therapy
WO2014030142A2 (en) Nitroimidazole compounds and their use in cancer therapy
HK1178153A1 (zh) 三唑并吡啶
CZ419199A3 (cs) Kyanoguanidiny jako inhibitory buněčné proliferace

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted